Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.33

Mkt cap

5.4M

Volume

23K

High

1.34

P/E Ratio

-1.07

52-wk high

6.80

Low

1.32

Div yield

N/A

52-wk low

0.92

Clearmind Medicine has received approval from the Israeli Ministry of Health to begin a Phase I/IIa clinical trial for treating Alcohol Use Disorder. This marks a significant step forward in the development of their treatment.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:15 pm

Clinical trials show psilocybin-assisted therapy's potential for treating Generalized Anxiety Disorder. Incannex Healthcare (NASDAQ:IXHL) conducted the Phase 2 study. Enveric Biosciences (NASDAQ:ENVB) announced non-binding deals to license drug compounds for mental health treatments. Compass Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), MindMed (NASDAQ:MNMD), and other companies reported financial results and business updates. AdvisorShares Psychedelics ETF (NYSE:PSIL) and several US-listed companies showed varied stock performance.

Portfolio Pulse from Lara Goldstein

March 04, 2024 | 6:48 pm

Clearmind Medicine Inc (NASDAQ:CMND) and SciSparc Ltd (NASDAQ:SPRC) have submitted three new international patent applications for MDMA, Ibogaine, and Ketamine compounds in collaboration. These applications aim to expand their intellectual property in the psychedelic space, with Clearmind now holding 27 granted patents and 24 pending applications. Additionally, Clearmind received approval to commence a phase 1/2a trial in Israel for alcohol use disorder using its CMND-100 oral capsule. CMND shares dropped 1.73% in premarket trading.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 12:30 pm

Clearmind Medicine has submitted three additional international patent applications for innovative compounds related to MDMA, Ibogaine, and Ketamine. This move signifies the company's ongoing efforts to expand its intellectual property portfolio in the psychedelic medicine space.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:30 pm

Clearmind Medicine has announced receiving approval to start a Phase I/IIa clinical trial for its drug CMND-100, aimed at treating Alcohol Use Disorder.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 12:08 pm

SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) have filed three patent applications for novel psychedelic compound combinations, aiming to enhance their market position and attract investments for mental health treatments. The patents involve combinations of LSD, psilocybin, DMT, and PEA, with the latter being the active ingredient in SciSparc's CannAmide. This collaboration seeks to protect their innovative therapies exclusively. Following the announcement, SPRC's shares rose by 2.74%, while CMND's shares fell by 7.79%.

Portfolio Pulse from Patricio Liddle

February 21, 2024 | 4:12 pm

SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) announced the submission of three international patent applications for novel proprietary combinations of psychedelic compounds, boosting their shares. This collaboration has led to 11 patent applications, aiming to strengthen their position in the psychedelic drug development market.

Portfolio Pulse from Erica Kollmann

February 20, 2024 | 6:29 pm

Clearmind Medicine Inc. has submitted three international patent applications for psychedelic-based compounds, in collaboration with SciSparc Ltd., under the Patent Cooperation Treaty. These efforts are part of their ongoing partnership to develop therapies for central nervous system disorders.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:17 pm

A new study highlights the potential of psychedelics like LSD and magic mushrooms in improving sexual function. The FDA has accepted an NDA from Lykos Therapeutics for MDMA-assisted therapy for PTSD, marking a significant step towards integrating psychedelic therapies into mainstream medicine. Despite the growing interest and decriminalization efforts in several states, federal law still prohibits psilocybin. Canadian research supports psilocybin therapy for end-of-life distress, and a Washington doctor is challenging the DEA for approval to use it with terminally ill patients. The psychedelics sector, including companies like Numinus Wellness and various psychedelics stocks, shows signs of growth and investor interest.

Portfolio Pulse from Lara Goldstein

February 15, 2024 | 1:36 pm

Clearmind Medicine Inc. has received divisional patent approval in China for its psychedelic-based treatment targeting binge behaviors. This approval strengthens the company's intellectual property portfolio, which includes 15 utility patent families and a total of 51 patents and pending applications globally. The company's MEAI molecule has shown promise in pre-clinical studies for regulating binge behaviors and addiction, particularly in relation to Alcohol Use Disorder and binge drinking.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.